Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Tardive Dyskinesia Excellence Forum

Tardive Dyskinesia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Rajeev Kumar MD
Videos
Overtreatment of Tardive Dyskinesia May Cause More Side Effects
11/08/2021
It is possible to overtreat tardive dyskinesia (TD) which can lead to other issues; clinicians should manage and reduce symptoms to improve quality of life, says Dr Rajeev Kumar.
It is possible to overtreat tardive dyskinesia (TD) which can lead to other issues; clinicians should manage and reduce symptoms to improve quality of life, says Dr Rajeev Kumar.
It is possible to overtreat...
11/08/2021
Psych Congress Network
Quiz
Can long-term anticholinergic medication exposure cause long-term consequences?
10/28/2021
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term...
10/28/2021
Psych Congress Network
Rakesh Jain
Videos
Using AIMS to Monitor Tardive Dyskinesia
10/14/2021
Psych Congress steering committee member Rakesh Jain, MD, MPH, discusses TD and how to modify AIMS to fit clinical practices.
Psych Congress steering committee member Rakesh Jain, MD, MPH, discusses TD and how to modify AIMS to fit clinical practices.
Psych Congress steering...
10/14/2021
Psych Congress Network
Niyati Butala
Q&As
Studying the Impact of Pharmacist-Driven Tardive Dyskinesia Screening
09/08/2021
In this Q&A session, Niyati Butala, Clinical Psychiatric Pharmacist, Riverside University Health System, Riverside, CA, discusses findings from the prospective quality improvement study “Impact of a pharmacist-driven tardive dyskinesia...
In this Q&A session, Niyati Butala, Clinical Psychiatric Pharmacist, Riverside University Health System, Riverside, CA, discusses findings from the prospective quality improvement study “Impact of a pharmacist-driven tardive dyskinesia...
In this Q&A session, Niyati...
09/08/2021
Psych Congress Network
TD
Podcasts
Discussing Quality of Life, Treatment Options for Tardive Dyskinesia
09/03/2021
Joohi Jimenez-Shahed, MD, and Rajeev Kumar, MD, FRCPC, answer questions about treatment options for Tardive Dyskinesia and its impact on quality of life.
Joohi Jimenez-Shahed, MD, and Rajeev Kumar, MD, FRCPC, answer questions about treatment options for Tardive Dyskinesia and its impact on quality of life.
Joohi Jimenez-Shahed, MD, and...
09/03/2021
Psych Congress Network
Dr Kosicek and Dr Jain
Podcasts
Tardive Dyskinesia Treatment With VMAT2 Inhibitors Doesn't Need to Alter Antipsychotic Therapy
08/13/2021
Dr Carmen Kosicek discusses best practices for implementing VMAT2 therapy while a patient is on antipsychotics as well as her concerns with the use of anticholinergics for TD.
Dr Carmen Kosicek discusses best practices for implementing VMAT2 therapy while a patient is on antipsychotics as well as her concerns with the use of anticholinergics for TD.
Dr Carmen Kosicek discusses best...
08/13/2021
Psych Congress Network
Dr Kosicek and Dr Jain
Podcasts
Insurance Coverage Tips for VMAT2 Inhibitors as Tardive Dyskinisia Treatment
08/09/2021
Carmen Kosicek, MSN, APNP, PMHNP-BC discusses insurance coverage of VMAT2 therapies for tardive dyskinesia and the usefulness of documenting an AIMS score.
Carmen Kosicek, MSN, APNP, PMHNP-BC discusses insurance coverage of VMAT2 therapies for tardive dyskinesia and the usefulness of documenting an AIMS score.
Carmen Kosicek, MSN, APNP,...
08/09/2021
Psych Congress Network
headshots
Podcasts
Treating TD: Best Practices for the Use of Antipsychotics, Anticholinergics, and VMAT2 Inhibitors
07/19/2021
Carmen Kosicek, MSN, APNP, PMHNP-BC and Rajeev Kumar, MD discuss the use of antipsychotics and anticholinergics in psychiatry, and VMAT2 inhibitors for the treatment of tardive dyskinesia (TD).
Carmen Kosicek, MSN, APNP, PMHNP-BC and Rajeev Kumar, MD discuss the use of antipsychotics and anticholinergics in psychiatry, and VMAT2 inhibitors for the treatment of tardive dyskinesia (TD).
Carmen Kosicek, MSN, APNP,...
07/19/2021
Psych Congress Network
Chepke
Q&As
Takeaways From Updated Guideline Recommendations for Tardive Dyskinesia Treatment Using VMAT2 Inhibitors
06/30/2021
Craig Chepke, MD, FAPA discusses the key takeaways for clinicians from the updated guideline recommendations for treatment of tardive dyskinesia (TD) with vesicular monoamine transporter 2 (VMAT2) inhibitors.
Craig Chepke, MD, FAPA discusses the key takeaways for clinicians from the updated guideline recommendations for treatment of tardive dyskinesia (TD) with vesicular monoamine transporter 2 (VMAT2) inhibitors.
Craig Chepke, MD, FAPA discusses...
06/30/2021
Psych Congress Network
Dr Chepke
Q&As
Vigilant Screening for Tardive Dyskinesia Among Recommendations to Mitigate Symptom Severity
06/22/2021
Clinicians should be vigilant about screening patients for TD as earlier detection is key in improving or slowing illness severity, suggests Craig Chepke, MD, FAPA in this Q&A that expands on his Elevate session.
Clinicians should be vigilant about screening patients for TD as earlier detection is key in improving or slowing illness severity, suggests Craig Chepke, MD, FAPA in this Q&A that expands on his Elevate session.
Clinicians should be vigilant...
06/22/2021
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement